Bart Nijmeijer

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

Inge Jedema, Renée M. Y. Barge, Vincent H. J. van der Velden et al. · Leukemia · 2003 · 138 citations

Hematological Malignancy, Gemtuzumab Ozogamicin, Cell Cycle-dependent Killing +12

Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs

Anna Majowicz, Bart Nijmeijer, Margit H. Lampen et al. · Molecular Therapy — Methods & Clinical Development · 2019 · 120 citations · Full text

Hemophilia B Patients, Aav5-human Fix, Autoimmune Disease +12

Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia

Susanne Badura, Tamara Tesanovic, Sylvia Wystub et al. · PLoS ONE · 2013 · 70 citations · Full text

Long–term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors

Bart Nijmeijer, Károly Szuhai, Henriëtte M. Goselink et al. · Experimental Hematology · 2009 · 61 citations

Hematological Malignancy, Medicine, Long–term Culture +8

Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model

Beate Schultheis, Bart Nijmeijer, Hua Yin et al. · Leukemia Research · 2011 · 59 citations

Spermatogenesis, Chromatin, Infertility +13